B4Deals
Lilly buys an injectables plant in Pleasant Prairie, Wisconsin, from Nexus
Lilly agreed to buy a finished plant near the Illinois border from Nexus Pharmaceuticals. The price was not disclosed.
Dateline
Pleasant Prairie, Wisconsin
Sterile production area in a pharmaceutical plant (Tula, Russia); stands in for an injectables line Photo: Press Centre of the Government of Tula Oblast, CC BY 4.0, via Wikimedia Commons (cropped)
In one lineAnother case of buying a working sterile site rather than building one.
What was announced
Lilly said it would acquire a manufacturing facility in Pleasant Prairie, Wisconsin, from Nexus Pharmaceuticals, a maker of generic injectable drugs. Terms were not disclosed.
What the plant is
The site was built for sterile injectables: drugs that are filled into vials or syringes in clean rooms. It was relatively new and already equipped.
Why it matters
Lilly was racing to add capacity for tirzepatide and other injected medicines. Buying a finished building skips site work, utilities and much of the construction time. The plant still needs to be set up for Lilly's products and inspected.
Pattern
The deal came months after Novo Holdings agreed to buy Catalent. In 2024 both large GLP-1 makers bought existing plants as well as building new ones.
The caveat
Lilly did not say which products would be made there or when.
What it changes for supply
A ready-made injectables plant adds filling space within months rather than years, which matters while demand for injected peptides still outruns supply.
Still open
What the plant will fill for Lilly and how long the transfer and inspection take.
SourceEli Lilly announcement, June 2024
Peptide Global covers how medicines are made and traded. Nothing here is medical advice.
